Palisade Bio (NASDAQ: PALI) has recently received a number of price target changes and ratings updates:
- 6/30/2026 – Palisade Bio was given a new $7.00 price target by Oppenheimer Holdings, Inc..
- 6/30/2026 – Palisade Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $2.00 price target on the stock.
- 6/29/2026 – Palisade Bio was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 6/27/2026 – Palisade Bio was downgraded by Wall Street Zen from “hold” to “sell”.
- 6/25/2026 – Palisade Bio was upgraded by LADENBURG THALM/SH SH to “strong-buy”.
- 6/9/2026 – Palisade Bio was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
See Also
- Five stocks we like better than Palisade Bio
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Palisade Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.
